FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008895328> ?p ?o ?g. }

• W3008895328 endingPage "1483" @default.
• W3008895328 startingPage "1476" @default.
• W3008895328 abstract "Prostate-specific antigen (PSA) is widely used to monitor treatment response in patients with metastatic castration-resistant prostate cancer. However, PSA measurements are considered only after 12 wk of treatment. We aimed to evaluate the prognostic value of early PSA changes after ¹⁷⁷Lu-labeled prostate-specific membrane antigen (¹⁷⁷Lu-PSMA) radionuclide treatment in metastatic castration-resistant prostate cancer patients. <b>Methods:</b> Men who were treated with ¹⁷⁷Lu-PSMA under a compassionate-access program at our institution and had available PSA values at baseline and at 6 wk after treatment initiation were included in this retrospective analysis. Patients were assigned to 3 groups on the basis of PSA changes: response (≥30% decline), progression (≥25% increase), and stable (<30% decline and <25% increase). The coprimary endpoints were overall survival and imaging-based progression-free survival. The secondary endpoints were PSA changes at 12 wk and PSA flare-up. <b>Results:</b> We identified 124 eligible patients with PSA values at 6 wk. A greater than or equal to 30% decline in PSA at 6 wk was associated with longer overall survival (median, 16.7 mo; 95% CI, 14.4–19.0) than stable PSA (median, 11.8 mo; 95% CI, 8.6–15.1) (<i>P</i> = 0.007) or PSA progression (median, 6.5 mo; 95% CI, 5.2–7.8) (<i>P</i> < 0.001). Patients with a greater than or equal to 30% decline in PSA at 6 wk also had a lower risk of imaging-based progression than patients with stable PSA (hazard ratio, 0.60; 95% CI, 0.38–0.94) (<i>P</i> = 0.02), whereas patients with PSA progression had a higher risk of imaging-based progression than patients with stable PSA (hazard ratio, 3.18; 95% CI, 1.95–5.21) (<i>P</i> < 0.001). The percentage changes in PSA at 6 and 12 wk were highly associated (<i>r</i> = 0.90; <i>P</i> < 0.001). Of 31 patients who experienced early PSA progression at 6 wk, 29 (94%) showed biochemical progression at 12 wk. Overall, only 1 (3%) of 36 patients with PSA progression at 6 wk achieved any PSA decline at 12 wk (1% of the entire cohort). The limitations of the study included its retrospective nature and the single-center experience. <b>Conclusion:</b> PSA changes at 6 wk after ¹⁷⁷Lu-PSMA initiation are an early indicator of long-term clinical outcome. Patients with PSA progression after 6 wk of treatment could benefit from a very early decision to switch treatment. PSA flare-up during ¹⁷⁷Lu-PSMA treatment is very uncommon. Prospective studies are now warranted to validate our findings and potentially inform clinicians earlier on the effectiveness of ¹⁷⁷Lu-PSMA." @default.
• W3008895328 created "2020-03-06" @default.
• W3008895328 creator A5002762582 @default.
• W3008895328 creator A5003688542 @default.
• W3008895328 creator A5012025332 @default.
• W3008895328 creator A5013631935 @default.
• W3008895328 creator A5038906134 @default.
• W3008895328 creator A5039159716 @default.
• W3008895328 creator A5057421384 @default.
• W3008895328 creator A5067941796 @default.
• W3008895328 creator A5068315207 @default.
• W3008895328 creator A5080877411 @default.
• W3008895328 date "2020-02-28" @default.
• W3008895328 modified "2023-10-16" @default.
• W3008895328 title "Early Prostate-Specific Antigen Changes and Clinical Outcome After ¹⁷⁷Lu-PSMA Radionuclide Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer" @default.
• W3008895328 cites W2026102934 @default.
• W3008895328 cites W2064016579 @default.
• W3008895328 cites W2094556422 @default.
• W3008895328 cites W2123098020 @default.
• W3008895328 cites W2145608595 @default.
• W3008895328 cites W2151930316 @default.
• W3008895328 cites W2159771669 @default.
• W3008895328 cites W2165542862 @default.
• W3008895328 cites W2172250854 @default.
• W3008895328 cites W2278392405 @default.
• W3008895328 cites W2296575890 @default.
• W3008895328 cites W2330292521 @default.
• W3008895328 cites W2397136240 @default.
• W3008895328 cites W2530940562 @default.
• W3008895328 cites W2661379965 @default.
• W3008895328 cites W2762824224 @default.
• W3008895328 cites W2771847508 @default.
• W3008895328 cites W2793000264 @default.
• W3008895328 cites W2799931007 @default.
• W3008895328 cites W2894392370 @default.
• W3008895328 cites W2898431834 @default.
• W3008895328 cites W2900829249 @default.
• W3008895328 cites W2901578258 @default.
• W3008895328 cites W2945708305 @default.
• W3008895328 cites W2960318035 @default.
• W3008895328 cites W2969742213 @default.
• W3008895328 cites W2972890374 @default.
• W3008895328 cites W2988034537 @default.
• W3008895328 doi "https://doi.org/10.2967/jnumed.119.240242" @default.
• W3008895328 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32111687" @default.
• W3008895328 hasPublicationYear "2020" @default.
• W3008895328 type Work @default.
• W3008895328 sameAs 3008895328 @default.
• W3008895328 citedByCount "27" @default.
• W3008895328 countsByYear W30088953282020 @default.
• W3008895328 countsByYear W30088953282021 @default.
• W3008895328 countsByYear W30088953282022 @default.
• W3008895328 countsByYear W30088953282023 @default.
• W3008895328 crossrefType "journal-article" @default.
• W3008895328 hasAuthorship W3008895328A5002762582 @default.
• W3008895328 hasAuthorship W3008895328A5003688542 @default.
• W3008895328 hasAuthorship W3008895328A5012025332 @default.
• W3008895328 hasAuthorship W3008895328A5013631935 @default.
• W3008895328 hasAuthorship W3008895328A5038906134 @default.
• W3008895328 hasAuthorship W3008895328A5039159716 @default.
• W3008895328 hasAuthorship W3008895328A5057421384 @default.
• W3008895328 hasAuthorship W3008895328A5067941796 @default.
• W3008895328 hasAuthorship W3008895328A5068315207 @default.
• W3008895328 hasAuthorship W3008895328A5080877411 @default.
• W3008895328 hasBestOaLocation W30088953281 @default.
• W3008895328 hasConcept C121608353 @default.
• W3008895328 hasConcept C126322002 @default.
• W3008895328 hasConcept C126894567 @default.
• W3008895328 hasConcept C143998085 @default.
• W3008895328 hasConcept C20417620 @default.
• W3008895328 hasConcept C2776235491 @default.
• W3008895328 hasConcept C2779256933 @default.
• W3008895328 hasConcept C2780192828 @default.
• W3008895328 hasConcept C2781406297 @default.
• W3008895328 hasConcept C2993559085 @default.
• W3008895328 hasConcept C71315377 @default.
• W3008895328 hasConcept C71924100 @default.
• W3008895328 hasConceptScore W3008895328C121608353 @default.
• W3008895328 hasConceptScore W3008895328C126322002 @default.
• W3008895328 hasConceptScore W3008895328C126894567 @default.
• W3008895328 hasConceptScore W3008895328C143998085 @default.
• W3008895328 hasConceptScore W3008895328C20417620 @default.
• W3008895328 hasConceptScore W3008895328C2776235491 @default.
• W3008895328 hasConceptScore W3008895328C2779256933 @default.
• W3008895328 hasConceptScore W3008895328C2780192828 @default.
• W3008895328 hasConceptScore W3008895328C2781406297 @default.
• W3008895328 hasConceptScore W3008895328C2993559085 @default.
• W3008895328 hasConceptScore W3008895328C71315377 @default.
• W3008895328 hasConceptScore W3008895328C71924100 @default.
• W3008895328 hasIssue "10" @default.
• W3008895328 hasLocation W30088953281 @default.
• W3008895328 hasOpenAccess W3008895328 @default.
• W3008895328 hasPrimaryLocation W30088953281 @default.
• W3008895328 hasRelatedWork W1987567565 @default.
• W3008895328 hasRelatedWork W2031954916 @default.
• W3008895328 hasRelatedWork W2038145494 @default.
• W3008895328 hasRelatedWork W2157439642 @default.
• W3008895328 hasRelatedWork W2381163510 @default.

• next